Centene faces a significant risk of customer churn in its standalone Medicare Part D prescription drug plans. This follows the federal government’s decision to terminate a premium stabilization subsidy.
The subsidy provided an estimated $3.6 billion to insurers to offset costs from the Inflation Reduction Act. This financial support ends after 2026.
Centene maintains the highest exposure to this change because approximately 90% of its Medicare drug members utilize standalone plans. This concentration far exceeds that of competitors like Humana or UnitedHealth Group.
The policy change threatens Centene’s Wellcare Value Script plan, which relies on a low-price strategy. The subsidy's end will likely trigger higher premiums for 25 million Americans enrolled in standalone Part D plans. These price increases may prompt enrollees to switch insurers.